Alpha 2.0
Login Register
» Articles » PMID: 35211311

Membranous Nephropathy Associated with Immunoglobulin G4-related Disease Successfully Treated with Obinutuzumab

Overview
Journal Clin Kidney J
Publisher Oxford University Press
Specialty Nephrology
Date 2022 Feb 25
PMID 35211311
Authors
Noemi E Ginthor
Katharina Artinger
Marion J Pollheimer
Martin H Stradner
Kathrin Eller
Affiliations
Soon will be listed here.
Abstract

Immunoglobulin G4 (IgG4)-releated disease is typically associated with interstitial nephritis, but rare cases of idiopathic membranous nephropathy as a renal manifestation have been described. Obinutuzumab was successfully used in refractory membranous nephropathy, but evidence for the treatment of IgG4-related disease with obinutuzumab is lacking. We report one patient's case with membranous nephropathy associated with IgG4-related disease who was treated with obinutuzumab following an anaphylactic reaction to rituximab. Obinutuzumab treatment resulted in a sustained complete remission of membranous nephropathy and a decrease of IgG4 to the normal range. This case demonstrates that membranous nephropathy associated with IgG4-related disease can be treated successfully with obinutuzumab.

Citing Articles

Obinutuzumab in membranous nephropathy: a potential game-changer in treatment.

Sessa C, Galeano D, Zanoli L, Delsante M, Rossi G, Morale W Drugs Context. 2025; 14.

PMID: 40017729 PMC: 11867167. DOI: 10.7573/dic.2024-9-1.

Obinutuzumab in Rituximab-resistant and recurrent membranous nephropathy: a case-series.

Sridharan K, Gopal B, Wilson S, Pham A, Hutton H J Nephrol. 2025; .

PMID: 39979558 DOI: 10.1007/s40620-025-02224-6.

A case of PLA2R-positive membranous nephropathy with subsequent development of IgG4-related disease.

Tanemoto F, Mimura I, Abe H, Nangaku M CEN Case Rep. 2024; .

PMID: 39514162 DOI: 10.1007/s13730-024-00941-8.

Obinutuzumab as Initial or Second-Line Therapy in Patients With Primary Membranous Nephropathy.

Su X, Wu B, Tie X, Guo X, Feng R, Qiao X Kidney Int Rep. 2024; 9(8):2386-2398.

PMID: 39156138 PMC: 11328588. DOI: 10.1016/j.ekir.2024.05.004.

Obinutuzumab in Refractory Membranous Nephropathy: A Case Series.

Lin Y, Han Q, Chen L, Wang Y, Ren P, Liu G Kidney Med. 2024; 6(8):100853.

PMID: 39100869 PMC: 11295861. DOI: 10.1016/j.xkme.2024.100853.

References
1.
Furie R, Aroca G, Cascino M, Garg J, Rovin B, Alvarez A . B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2021; 81(1):100-107. PMC: 8762029. DOI: 10.1136/annrheumdis-2021-220920. View
2.
Mossner E, Brunker P, Moser S, Puntener U, Schmidt C, Herter S . Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood. 2010; 115(22):4393-402. PMC: 2881503. DOI: 10.1182/blood-2009-06-225979. View
3.
Carruthers M, Topazian M, Khosroshahi A, Witzig T, Wallace Z, Hart P . Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis. 2015; 74(6):1171-7. DOI: 10.1136/annrheumdis-2014-206605. View
4.
Wallace Z, Naden R, Chari S, Choi H, Della-Torre E, Dicaire J . The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease. Ann Rheum Dis. 2019; 79(1):77-87. DOI: 10.1136/annrheumdis-2019-216561. View
5.
Klomjit N, Fervenza F, Zand L . Successful Treatment of Patients With Refractory PLAR-Associated Membranous Nephropathy With Obinutuzumab: A Report of 3 Cases. Am J Kidney Dis. 2020; 76(6):883-888. DOI: 10.1053/j.ajkd.2020.02.444. View